Want to join the conversation?
$AMGN's OpEx decreased 4% YoverY in 4Q15 and remained flat for the full year. R&D expenses fell 10% YoverY in 4Q15, driven by savings from transformation and process improvement efforts, as well as a $60MM upfront payment in 4Q14 related to its cancer immunotherapy collaboration with $KITE.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.